Savara Inc (NASDAQ:SVRA) Updates On U.S. Composition Of Matter Patent


Savara Inc (NASDAQ:SVRA) reported the recent issuance of patent for dry powder vancomycin compositions & related methods by the USPTO. The patent will offer intellectual property protection in the United States for the AeroVanc plan and will expire by 2032.

This gives company vital composition of matter protection for AeroVanc plan in the United States, the leading market for the offering, and is a major component of the firm’s market protection plan which also comprises Qualified Infectious Disease and Orphan Drug Product protection.

The highlights

Savara has even obtained a Notice of Allowance for AeroVanc. This will serve as authorized communication that the inspection of the patent application has been closed. Once released, the patent will offer protection for its product in Canada until 2032. The firm has parallel patent applications for AeroVanc in distinct phases of prosecution in other major markets across the world.

The prevalence of MRSA pulmonary infection in cystic fibrosis subjects has continued to increase in the U.S., and the infection has been linked with increased use of IV, increased hospitalizations, antibiotics, a faster drop of lung function and shortened life-expectancy. In spite of inhaled antibiotics accessible to CF patients for more than 10 years to cure non-MRSA infections, there exists no authorized inhaled antibiotic for the cure of MRSA in CF. Savara’s AeroVanc is being advanced to resolve this unmet medical need in cystic fibrosis.

In a Phase 2 trial in cystic fibrosis subjects with MRSA infection, AeroVanc lessened MRSA density in sputum, as well as demonstrated promising trends of progress in respiratory symptoms and lung function, and prolongation of the time to application of other antibiotics, with encouraging responses in patients aged 21 years or below.

Savara intends to commence a pivotal Phase III trial of AeroVanc for the cure of MRSA in cystic fibrosis patients in Q3 2017.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.